Administrative Supplement for Peptide Synthesizer

南卡罗来纳州大学（UofSC）的COBRE靶向治疗中心（CTT） 支持旨在开发新的和更有效的药物类别的研究， 通过将这些药物瞄准在疾病中起关键作用的分子和细胞靶点， 疾病药物设计和合成核心提供了合成化学和 基于结构的药物设计资源，这些是药物发现过程的关键部分。 许多正在进行的项目涉及蛋白质-蛋白质相互作用的靶向， 目标验证方法的一个重要方面是鉴定代表以下起点的肽配体： 策略的应用可以将这些转化为更像药物的化合物。的另一种方法 药物发现是固相合成DNA编码的化学库， 与混合和分裂库的方法将允许显着的化学多样性， 生成的.我们寻求获得一个国家的最先进的固相合成器，可用于 快速生成肽、肽模拟物和其他片段导向化合物的文库 并通过并行合成有效地实现。这将大大提高 DDSC在早期药物发现中发挥作用，并支持目前正在进行或计划进行的多个项目 在不久的将来。

The COBRE Center for Targeted Therapeutics (CTT) at the University of South Carolina (UofSC) supports research that seeks to develop new and more effective classes of drugs against various diseases, by aiming these drugs at molecular and cellular targets that play a key role in the disease. The Drug design and Synthesis Core provides access to synthetic chemistry and structure-based drug design resources, and these are a critical part of the drug discovery process. Many of the projects being pursued involve the targeting of protein-protein interactions and part of the target validation approach is to identify peptide ligands that represent starting points for application of strategies can convert these into more drug-like compounds. Another approach to drug discovery is the solid phase synthesis of DNA encoded chemical libraries which combined with the mix and split library approaches would allow significant chemical diversity to be generated. We seek to acquire a state-of-the-art solid phase synthesizer which can be used to generate libraries of peptides, peptidomimetics and other fragment-oriented compounds rapidly and efficiently through parallel synthesis. This will substantially increase the capabilities of the DDSC in early-stage drug discovery and support multiple projects currently underway or planned for the near future.